Leerink Initiates Coverage of Exact Sciences With Outperform Rating

Apr 17, 2017

|

This article has been updated with a correction to the current market penetration for Cologuard. The correct figure is 1 percent, not 42 percent as originally reported.

NEW YORK (GenomeWeb) – Leerink on Monday initiated coverage of molecular diagnostics firm Exact Sciences with an Outperform rating and a 12-month $30 price target on the company's stock price.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Leerink Initiates Coverage of Exact Sciences With Outperform Rating

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

What's Popular?

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Fulgent Inks $125M Equity Distribution Agreement With Piper Sandler

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

Sponsorships